|Bid||5.40 x 1200|
|Ask||5.41 x 800|
|Day's range||5.32 - 5.52|
|52-week range||2.50 - 9.49|
|Beta (5Y monthly)||2.68|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.43|
CAMBRIDGE, Mass., February 08, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway. SER-155, an investigational oral microbiome therapeutic, is designed to reduce the incidence of gastrointestinal (GI) infections, bloodstream infections, and graft versus host disease (GvHD) in individuals undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
CAMBRIDGE, Mass., February 03, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on February 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its common stock to eleven new employees, consisting of stock options to purchase an aggregate of 32,500 shares of common stock and restricted stock units ("RSUs"), cov
The last three months have been tough on Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders, who have seen the share...